TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alembic Pharmaceuticals Limited ( (IN:APLLTD) ) has issued an update.
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Diltiazem Hydrochloride Tablets USP in various dosages. This approval marks a significant milestone for Alembic, enhancing its portfolio of USFDA-approved products and strengthening its position in the global pharmaceutical market. The approval is expected to positively impact the company’s operations and market presence, offering stakeholders potential growth opportunities.
More about Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company, established in 1907 and headquartered in India. It is publicly listed and focuses on manufacturing and marketing generic pharmaceutical products globally. Alembic is recognized as a leader in branded generics in India, with its products being approved by regulatory authorities in many developed countries, including the USFDA.
Average Trading Volume: 11,217
Technical Sentiment Signal: Hold
Current Market Cap: 180.3B INR
Learn more about APLLTD stock on TipRanks’ Stock Analysis page.